$6.09 +0.33 (%) Cyclacel Pharmaceuticals Inc - NASDAQ

Sep. 28, 2016 | 02:50 PM

Partner Headlines

  1. Benzinga's Weekend M&A Chatter

    Benzinga | Nov. 29, 2015 | 19:44PM EST
  2. Benzinga's Top Initiations

    Benzinga | Oct. 16, 2015 | 09:27AM EST
  3. Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas

    Benzinga | Sep. 17, 2015 | 07:04AM EST
  4. Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,

    Benzinga | Jul. 2, 2015 | 07:04AM EST
  5. Wilbur Ross Buys Two New Stakes in First Quarter

    GuruFocus | Jun. 15, 2015 | 16:59PM EST
  6. Morning Market Losers

    Benzinga | Dec. 16, 2014 | 09:57AM EST
  7. Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL Rearrangements

    Benzinga | Sep. 18, 2014 | 07:02AM EST
  8. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  9. Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering

    Benzinga | Apr. 9, 2014 | 16:06PM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 4, 2014 | 08:22AM EST
  11. Earnings Scheduled For March 25, 2014

    Benzinga | Mar. 25, 2014 | 05:08AM EST
  12. Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH

    Benzinga | Dec. 9, 2013 | 07:07AM EST
  13. Cyclacel Pharma Announces Data Safety Monitoring Board Recommends Continuation of SEAMLESS Study of Sapacitabine in AML

    Benzinga | Nov. 25, 2013 | 07:18AM EST
  14. Morning Market Losers

    Benzinga | Sep. 23, 2013 | 10:14AM EST
  15. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 20, 2013 | 08:10AM EST
  16. Cyclacel's Seliciclib to be Evaluated for RA

    Benzinga | Aug. 12, 2013 | 16:01PM EST
  17. Cyclacel Comments on Key Business Objectives for 2013

    Benzinga | Jan. 7, 2013 | 00:22AM EST
  18. Aspire Capital Fund to Purchase Up to $20M of Cyclacel Common Stock for $6.29/Share

    Benzinga | Dec. 17, 2012 | 00:29AM EST
  19. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 10, 2012 | 01:11AM EST
  20. Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

    Benzinga | Dec. 4, 2012 | 02:12AM EST
  21. Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 16, 2012 | 11:06AM EST
  22. Stocks Hitting 52-Week Highs

    Benzinga | Oct. 15, 2012 | 05:06AM EST
  23. Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

    Benzinga | Sep. 13, 2012 | 01:05AM EST
  24. Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 14, 2012 | 13:30PM EST
  25. Earnings Scheduled For May 14

    Benzinga | May. 13, 2012 | 20:12PM EST
  26. Benzinga's Microcap Movers for Monday February 6, 2012

    Benzinga | Feb. 6, 2012 | 14:51PM EST
  27. Feuerstein: Earlier Cyclacel PR Buries Seliciclib Drug Re-Analysis as "Insufficient", Sees as a Negative

    Benzinga | Jan. 11, 2012 | 05:30AM EST
  28. Cyclacel Provides Corporate Update at OneMedForum Conference; Re-Analysis "Insufficient"

    Benzinga | Jan. 11, 2012 | 05:27AM EST
  29. Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML

    Benzinga | Dec. 12, 2011 | 06:02AM EST
Trading Center